ISBT is the global knowledge network for Transfusion Medicine
The International Society of Blood Transfusion (ISBT) is a scientific society that was founded in 1935. Since that time the ISBT has grown in to an international society where transfusion medicine professionals from across the globe come together and do the one thing they do best: share knowledge to improve the safety of blood transfusion worldwide.
We believe that with the power of knowledge we can improve the safety of blood transfusion worldwide. Professionals from over 100 countries already share their knowledge with this international transfusion medicine community by being a member of ISBT.
We are an international community of professionals sharing knowledge to enhance transfusion practice.
We achieve this by:
- Providing opportunities for advancing knowledge and education
- Advocacy for the welfare of blood donors and transfusion recipients
Our most important activity is to promote science and education related to blood, cells and transplantation. We have created an educational platform; ISBT Education. This eLearning facility includes webcasts of ISBT congress presentations, recordings of Webinars and Live Journal Clubs, and a library of transfusion guidelines. In addition we:
- Encourage and support the ISBT Working Parties that focus on the study of specific topics.
- Publish the scientific journals Vox Sanguinis and the Science Series and provide other high quality educational print and electronic material.
- Organise International and Regional congresses.
- Support and participate in regional workshops, seminars and congresses either financially or by use of the ISBT logo.
- Provide financial support to professionals from low and medium development index countries.
The ISBT has ANBI status. ANBI is the Dutch abbreviation for Public Benefit Organisation by The Dutch Tax and Customs Administration.
The ISBT Central Office is located in the centre of Amsterdam, the Netherlands. With five fulltime colleagues and one part time colleague we:
- Provide administrative and organisational support for the Board of Directors and Executive Committee.
- Manage membership matters.
- Coordinate International and Regional Congresses.
- Facilitate content creation for ISBT Education.
- Support the Standing Committees and Working Parties.
- Edit and arrange for the distribution of ISBT's quarterly magazine Transfusion Today.
- Operate as System Administrator for the ISBT website.
The Standing Committees comprise a Chairperson and individual members chosen for their experience in the particular field of work. The ISBT has a number of Standing Committees:
The ISBT Board of Directors is entrusted with the corporate governance and overall management of ISBT. The Board of Directors consists of the Executive Committee and nine Regional Directors. The Board delegates specific management and administrative functions to the Executive Committee which also works to ensure that the ISBT acts in accordance with Board decisions and with resolutions approved by members at the annual General Assembly. Read more
The Young Professionals Council consists of young, bright minds across the globe, working in transfusion medicine and under 40 years of age. The council's purpose is to engage and enrich Young Transfusion Medicine Professionals, with the aim of increasing ISBT membership value and active participation in the Society's activities. Read More
In May 2014 during the World Health Assembly in Geneva, Luc Noel (WHO Special Advisor- Service Delivery and Safety for the Initiative on Medical Products of Human Origin) set up a meeting involving representatives of four nongovernmental organisations in official relations with WHO to discuss a proposal relating to Medical Products of Human Origin (MPHO). The four organisations involved were The Transplantation Society (TTS), the Worldwide Network for Blood and Marrow Transplantation (WBMT), the International Society for Blood Transfusion (ISBT) and the International Council for Commonality in Blood Banking Automation (ICCBA).
Click here to download the ethical principles guiding the donation and procurement of Medical Products of Human Origin.
We are honoured that seven companies are supporting ISBT as Gold Corporate partners:
We thank our Silver Corporate Partners:
We are thankful for the support of our Bronze Corporate partners:
Their valued support enables ISBT to continue facilitating knowledge about transfusion medicine and promoting a safe blood supply.
All levels of Corporate partners enjoy priority allocation at ISBT congresses for exhibition space and satellite symposia. Platinum and Gold partners have the opportunity to meet with members of the ISBT Executive committee and to work with ISBT when appropriate on educational activities.
We offer four levels of partnership:
For further information please contact Judith Chapman.
Abbott is a health care company that is devoted to discovering new medicines, new technologies and new ways to manage health. The products span the continuum of care, from nutritional products laboratory diagnostics through medical devices and pharmaceutical therapies. For more information about Abbott, please visit their website: www.abbott.com.
Grifols is a global healthcare company whose mission is to improve the health and well being of people around the world. They accomplish this mission by producing life-saving protein therapies for patients and by providing hospitals, pharmacies and healthcare professionals with the tools they need to deliver expert medical care. For more information about Grifols, please visit: www.diagnostic.grifols.com.
Immucor plays a role in making blood transfusions safe for patients around the world. They market a complete line of traditional immunohematology reagents and fully automated instruments as well as data management software. For more information about Immcuor, please visit: www.immucor.com.
With over 30 years of experience developing, manufacturing and commercializing blood-grouping reagents for the global transfusion diagnostics market, Quotient is focused on providing high quality, high value immunohematology products to hospitals and blood banks around the world. Quotient is nearing the commercialization of MosaiQ™, a next generation automation platform for transfusion diagnostics. For more information about Quotient, please visit: www.quotientbd.com
Roche provides diagnostic tests and automation platforms used worldwide to improve the safety of blood products, increase laboratory efficiency, diagnose disease, monitor response to therapy and identify gene-based factors that may aid in treatment selection. For more information about Roche, please visit: www.roche.com.
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today.
Please visit: www.terumobct.com
B Medical Systems is solely dedicated to the research, development and the manufacture of medical technology equipment. This includes equipment for the vaccine cold chain, refrigerators, freezers, storage and solutions for the safe blood and blood components transport, storage, treatment and management. For more information about B medical Systems please visit: www.bmedicalsystems.com
bioMérieux has been a global leader in in vitro diagnostics for more than 50 years, They have always been driven by a pioneering spirit and unrelenting commitment to improve public health worldwide. Today, in more than 150 countries through 43 subsidiaries and a large network of distributors, bioMérieux provides diagnostic solutions that improve patient health and ensure consumer safety. Please visit: http://www.biomerieux.com/ for more information.
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as Chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. For more information please visit: http://cerus.com/
DiaSorin develops, produces and distributes immunoreagent kits for clinical diagnostics. By making tests available that can provide guidance in making clinical decisions, DiaSorin has contributed to improving the delivery of health care and reducing its costs. For more information about DiaSoring, please visit: www.diasorin.com/en.
Macopharma works to design innovative solutions and quality products that are effective in meeting the needs of both patients and healthcare providers. Every day across the world, Macopharma employees are dedicated to making therapeutic practices easier, better and safer. That is what they mean by the slogan “Designed for life.” For more information about Macopharma please visit: https://www.macopharma.com/
ISBT and AABB recognise that their missions, aims, memberships and activities have common elements and while these may partially overlap they acknowledge that this provides a potential for synergy. The organisations believe in working together to utilise their respective strenghts and resources to pursue mutual and common interests. These are outlined in a memorandum of understanding signed in June 2017.
Click for more information.
Working with 194 Member States, across six regions, and from more than 150 offices, WHO staff are united in a shared commitment to achieve better health for everyone, everywhere. Their primary role is to direct and coordinate international health within the United Nations system. The main areas of work are health systems; health through the life-course; noncommunicable and communicable diseases; preparedness, surveillance and response; and corporate services.
Click for more information.
The International Collaboration for Transfusion Medicine Guidelines (ICTMG) was established in 2011 and has 28 members from 10 countries. The aims of the ICTMG are to develop evidence based transfusion medicine guidelines to optimize transfusion care by using a widely collaborative international effort with consistent up-to-date methodology and to establish consistency while reducing redundancy in guideline development. The purpose of developing guidelines is to help improve the quality and consistency of transfusion care. Guidelines are intended to condense the abundant scientific knowledge into a usable format, decrease variation in transfusion practice, support efficient utilization of resources and priories research activities. The ICTMG guidelines are intended for health care providers providing transfusion, hospital transfusion medicine services, blood agencies, health care systems and Transfusion Societies.
ISBT and AfSBT have the capacity and knowledge to facilitate and share resources that will promote the development and strengthening of the practice of blood transfusion and the development of human resource capacity in Africa. Each of the Societies agrees in principle to utilise their respective strengths and resources to pursue mutual interests. These are outlined in a memorandum of understanding signed in 2018.
Click for more information.
The European Blood Alliance (EBA) is an association of not for profit Blood Establishments, with 26 members throughout the European Union and EFTA States. The official seat and office of the Alliance is Amsterdam, the Netherlands. The EBA is guided by 5 core values: Donor care, patient safety, voluntary non-remunerated blood donation, openness through information sharing and excellence through evidence.
Click for more information.
The Brazilian Association of Hematology, Hemotherapy and Cell Therapy (ABHH) was born from the merger of the Brazilian Society of Hematology and Hemotherapy (SBHH) with the Brazilian College of Hematology (CBH). The association has more than four thousand members. The mission of ABHH is:
- Represent the community of hematology, hemotherapy and cell therapy professionals
- Promote, guide and defend policies and measures that determine ethics, recognition, dignity and appreciation of the specialty
- Caring for quality in patient care and specialty services
- Guarantee to younger professionals technical and educational programs to guide quality training and encourage adequate entry into the
- Encourage multidisciplinarity in the development of professionals in the area as a way of supporting joint initiatives for constant improvement in
education, care and research in the areas involved